An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

Inclusion Criteria Patients must have: * Patients \> 18 months of age with history of positive serology for HIV-1 infection or patients \<= 18 months of age with history of positive viral culture, detectable p24 antigen, or positive peripheral blood mononuclear cell macro culture. * Patients \>= 13 years of age with a CD4+ cell count \<= 200 cells/mm3. Patients \< 13 years of age with a CD4% \<= 14% or a 50% decrease in CD4% in the past 6 months if the previous CD4% was \>=20%. * Patient has failed or is intolerant to currently approved treatments for HIV-1 infection and is unable to participate in a controlled viramune clinical trial. * Written and informed consent from a parent or guardian for patients \< 18 years of age. * Patient or guardian is willing and able to follow protocol requirements. (PER AMENDMENT 1/29/97: * Enrollment is closed to adults, as of Jan. 29th only pediatric patients will be enrolled.) Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Patient qualifies for participation in an actively accruing Viramune controlled clinical trial. Concurrent Medication: Excluded: * Dicumarol, Warfarin, and other anticoagulant medications. * Tolbutamide. * Investigational drugs, all protease inhibitors, and all other non-nucleoside transcriptase inhibitors. * Neurotoxic drugs. * Cimetidine. * Erythromycin. Required: Patient has failed or is intolerant to currently approved treatments for HIV-1 infection.